Moneycontrol PRO
Loans
HomeNewsShasunpharma

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Expect revenue of around Rs 400 cr in Q4: Shasun Pharma

    Abhaya Kumar of Shasun Pharma believes Q4 is always a better quarter and hopes to maintain revenue growth and EBITDA at around current levels.

  • Find out: FMCG, pharma, Oil& Gas who will lead Q4 earnings?

    Find out: FMCG, pharma, Oil& Gas who will lead Q4 earnings?

    The fourth quarter earnings will begin from Friday. In an interview to CNBC-TV18, Varatharajan Sivasankaran of ICICI Securities outlined his expectations from stocks across various sectors.

  • Sun Pharma to continue holding stake in Taro, says VP Fin

    Sun Pharma to continue holding stake in Taro, says VP Fin

    Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma said the company will continue to hold stake in Taro despite their termination of the merger agreement.

  • Shasun Pharma eyes robust Q4 growth, says MD

    Shasun Pharma eyes robust Q4 growth, says MD

    Abhaya Kumar, MD of Shasun Pharmaceuticals said the Q3 margins were stressed owing to price pressures from the US.

  • Growth in margins sustainable going forward: Shasun Pharma

    Growth in margins sustainable going forward: Shasun Pharma

    Abhaya Kumar, managing director of Shasun Pharmaceuticals, tells CNBC-TV18 that the jump in margins is sustainable going ahead.

  • Merck JV will earn revenues in a few years, says Sun Pharma

    Merck JV will earn revenues in a few years, says Sun Pharma

    In an exclusive interview with CNBC-TV18, Uday Baldota of Sun Pharma says the company saw significant growth in Sun Pharma’s standalone numbers, while as well "Taro reported strong margins this quarter." The leading drugmaker discloses that the company is "bearing additional costs for some non-revenue generating businesses."

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347